Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

GESTODENE IMPURITY I CRS (0.01 MG)

GESTODENE IMPURITY I CRS (0.01 MG)

NA

DISCOVER
AMIKACIN FOR SYSTEM SUITABILITY CRS (15 MG)

AMIKACIN FOR SYSTEM SUITABILITY CRS (15 MG)

39831-55-5

DISCOVER
VEDAPROFEN  IMPURITY MIXTURE CRS (0.006 MG)

VEDAPROFEN IMPURITY MIXTURE CRS (0.006 MG)

NA

DISCOVER
ADAPALENE FOR PEAK IDENTIFICATION CRS (2.02 MG)

ADAPALENE FOR PEAK IDENTIFICATION CRS (2.02 MG)

106685-40-9

DISCOVER
ADAPALENE IMPURITY C CRS (10 MG)

ADAPALENE IMPURITY C CRS (10 MG)

NA

DISCOVER
ADAPALENE CRS (100 MG)

ADAPALENE CRS (100 MG)

106685-40-9

DISCOVER
BUPRENORPHINE FOR SYSTEM SUITABILITY CRS - * PSY (10 MG)

BUPRENORPHINE FOR SYSTEM SUITABILITY CRS - * PSY (10 MG)

52485-79-7

DISCOVER
TOLNAFTATE FOR SYSTEM SUITABILITY CRS (10 MG)

TOLNAFTATE FOR SYSTEM SUITABILITY CRS (10 MG)

2398-96-1

DISCOVER
ETHINYLESTRADIOL FOR SYSTEM SUITABILITY CRS (1.01 MG)

ETHINYLESTRADIOL FOR SYSTEM SUITABILITY CRS (1.01 MG)

57-63-6

DISCOVER
ORBIFLOXACIN CRS (200 MG)

ORBIFLOXACIN CRS (200 MG)

113617-63-3

DISCOVER
SPIKE LAVENDER OIL CRS (400 µL)

SPIKE LAVENDER OIL CRS (400 µL)

8016-78-2

DISCOVER
PHENTOLAMINE MESILATE CRS (10MG)

PHENTOLAMINE MESILATE CRS (10MG)

65-28-1

DISCOVER